Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last --
Change Today 0.00 / 0.00%
Volume 0.0
4174 On Other Exchanges
4174 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

obi pharma inc (4174) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OBI PHARMA INC (4174)

Related News

No related news articles were found.

obi pharma inc (4174) Related Businessweek News

No Related Businessweek News Found

obi pharma inc (4174) Details

OBI Pharma, Inc. engages in the research and development of medicines. It offers OBI-888, an anti-globo H monoclonal antibody that could complement the active immunotherapy of cancer, principally for the patients undergoing radiation and/or chemo therapies. The company serves patients in hospitals and cancer treatment centers. It assists aesthetics clinics and medical markets through a network of distributors and dealers in Taiwan, China, Hong Kong, and the United States. The company was founded in 2002 and is based in Taipei, Taiwan. OBI Pharma, Inc. is a subsidiary of Optimer Pharmaceuticals.

Founded in 2002

obi pharma inc (4174) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

obi pharma inc (4174) Key Developments

OBI Pharma, Inc. Presents at BIO-Europe 2015, Nov-02-2015

OBI Pharma, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

OBI Pharma, Inc. Enters Exclusive Agreement with Merck for Rights to Dificid (fidaxomicin) in Taiwan

OBI Pharma, Inc. announced an agreement with MSD, known as Merck in the United States and Canada, through a subsidiary transferring exclusive rights to develop and commercialize Dificid (fidaxomicin) in Taiwan to MSD. This agreement will enable the launch of Dificid in Taiwan utilizing MSD's extensive market expertise and knowledge, with the potential to benefit patients in Taiwan suffering from Clostridium Difficile-Associated Diarrhea (CDAD). Under the terms of the agreement, OBI Pharma will receive an initial up-front payment of USD 3.0 million from MSD and is eligible to receive royalties and payments associated with the completion of certain undisclosed milestones. MSD will be responsible for all future costs associated with commercialization, development, and manufacturing of DIFICID in Taiwan.

OBI Pharma, Inc., Annual General Meeting, Jun 03, 2015

OBI Pharma, Inc., Annual General Meeting, Jun 03, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4174:TT 638.00 TWD +9.00

4174 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4174.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4174 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 14.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OBI PHARMA INC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at